Prothena (PRTA) Scheduled to Post Quarterly Earnings on Wednesday

Prothena (NASDAQ:PRTA) is scheduled to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect Prothena to post earnings of ($1.21) per share for the quarter.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.03). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $2.15 million. During the same quarter last year, the firm earned $0.12 EPS. The company’s revenue was down 99.4% on a year-over-year basis. On average, analysts expect Prothena to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Prothena Stock Up 1.4 %

Shares of NASDAQ:PRTA traded up $0.33 during trading hours on Monday, hitting $23.26. 50,332 shares of the company’s stock traded hands, compared to its average volume of 731,791. The business has a fifty day moving average price of $24.65 and a 200-day moving average price of $30.85. Prothena has a 1 year low of $19.65 and a 1 year high of $79.38.

Wall Street Analyst Weigh In

A number of analysts have weighed in on PRTA shares. Oppenheimer reduced their target price on Prothena from $98.00 to $80.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 20th. StockNews.com cut shares of Prothena from a “hold” rating to a “sell” rating in a research report on Monday, February 19th. JMP Securities raised their target price on shares of Prothena from $81.00 to $85.00 and gave the stock a “market outperform” rating in a research report on Friday, February 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a report on Wednesday, April 10th. Finally, Bank of America restated a “neutral” rating and set a $38.00 price objective (down from $68.00) on shares of Prothena in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.14.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.